Pre-Existing Immunity with High Neutralizing Activity to 2009 Pandemic H1N1 Influenza Virus in Shanghai Population

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Liu, Xiaoqing ^a   Liu, Yuan ^a   Zhang, Yanjun ^a   Chen, Zhihui ^b   Tang, Ziwei ^a   Xu, Qingqiang ^a   Wang, Yue ^c   Zhao, Ping ^a   Qi, Zhongtian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c National Institute for Viral Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DNA VACCINE; EPITOPE; HEMAGGLUTININ ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHINA; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; EMBRYO; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNOASSAY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRE EXISTING IMMUNITY; SEASONAL INFLUENZA; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CELL LINE; CHINA; CROSS REACTIONS; EPITOPES, B-LYMPHOCYTE; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MICE; MIDDLE AGED; NEUTRALIZATION TESTS; PANDEMICS; YOUNG ADULT;

EID: 84875101603     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058810     Document Type: Article

References (43)

1. Cao J, Wang Y, Song H, Meng Q, Sheng L, et al. (2009) Hepatitis A outbreaks in China during 2006: application of molecular epidemiology. Hepatol Int 3: 356-363.
2. Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, et al. (2009) Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 361: 674-679.
3. Mathews JD, McCaw CT, McVernon J, McBryde ES, McCaw JM, (2007) A biological model for influenza transmission: pandemic planning implications of asymptomatic infection and immunity. PLoS One 2: e1220.
4. Mathews JD, McBryde ES, McVernon J, Pallaghy PK, McCaw JM, (2010) Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC Infect Dis 10: 128.
5. Scalera NM, Mossad SB, (2009) The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad Med 121: 43-47.
6. Chen H, Wang Y, Liu W, Zhang J, Dong B, et al. (2009) Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis 15: 1849-1850.
7. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 106: 20365-20370.
8. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952.
9. ItohY, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
10. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, et al. (2010) High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 15pii: 19478.
11. Kwan-Gett TS, Baer A, Duchin JS, (2009) Spring 2009 H1N1 influenza outbreak in King County, Washington. Disaster Med Public Health Prep 3Suppl 2: S109-116.
12. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, et al. (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375: 1100-1108.
13. Xing Z, Cardona CJ, (2009) Preexisting immunity to pandemic (H1N1) 2009. Emerg Infect Dis 15: 1847-1849.
14. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
15. Zhang Y, Li X, Zhang F, Wu J, Tan W, et al. (2009) Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochem Biophys Res Commun 387: 405-408.
16. Democratis J, Pareek M, Stephenson I, (2006) Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother 58: 911-915.
17. Gerdil C, (2003) The annual production cycle for influenza vaccine. Vaccine 21: 1776-1779.
18. Subbarao K, (1999) Influenza vaccines: present and future. Adv. Virus Res 54: 349-373.
19. Du N, Zhou J, Lin X, Zhang Y, Yang X, et al. (2010) Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. J Virol 84: 7822-7831.
20. Lin X, Zhou J, Zhang Y, Wu J, Zhang F, et al. (2009) Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. Biochem Biophys Res Commun 390: 1305-1308.
21. Liu Y, Liu X, Fang J, Shen X, Chen W, et al. (2010) Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses. Vaccine 29: 183-190.
22. Wu J, Zhang F, Wang M, Xu C, Song J, et al. (2010) Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses. PLoS One 5: e15825.
23. Zhang Y, Lin X, Wang G, Zhou J, Lu J, et al. (2010) Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLoS One 5: e9167.
24. Fang J, Chen Z, Liu X, Li H, Wang J, Shen X, Chen W, et al. (2011) Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice. J Virol Methods 173(2): 314-319.
25. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. Am J Epidemiol 27: 493-497.
26. Brownlee GG, Fodor E, (2001) The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos Trans R Soc Lond B Biol Sci 356(1416): 1871-1876.
27. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-376.
28. Tang JW, Tambyah PA, Wilder-Smith A, Puong KY, Shaw R, et al. (2010) Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerg Infect Dis 16: 874-876.
29. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JR, et al. (2010) Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328: 357-360.
30. Rizzo C, Rota MC, Bella A, Alfonsi V, Declich S, et al. (2010) Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 28(20): 3558-3562.
31. Chi CY, Liu CC, Lin CC, Wang HC, Cheng YT, et al. (2010) Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 17(12): 1958-1962.
32. Dowdle WR, Hattwick MA, (1977) Swine influenza virus infections in humans. J Infect Dis 136Suppl:S386-389.
33. Olsen CW, (2002) The emergence of novel swine influenza viruses in North America. Virus Res 85: 199-210.
34. Taubenberger JK, Hultin JV, Morens DM, (2007) Discovery and characterization of the 1918 pandemic influenza virus in historical context. Antivir Ther 12(4 Pt B): 581-591.
35. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solórzano A, et al. (2005) Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310: 77-80.
36. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, et al. (2010) Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375(9708): 56-66.
37. Lemaitre M, Leruez-Ville M, De Lamballerie XN, Salez N, Garrone P, et al. (2010) Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. Clin Microbiol Infect 17(5): 732-737.
38. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le Mt, et al. (2010) A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88(3): 249-255.
39. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208(1): 181-193.
40. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, et al. (2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484-487.
41. Pascua PN, Song MS, Lee JH, Park KJ, Kwon HI, et al. (2009) Evaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infection. PLoS One 4: e8431.
42. Centers for Disease Control and Prevention (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58(19): 521-524.
43. Centers for Disease Control and Prevention (2009) Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1)-United States, May-June 2009. MMWR Morb Mortal Wkly Rep 58: 1241-1245.